Dynavax Technologies Corporation (DVAX)vsMerck & Company Inc (MRK)
DVAX
Dynavax Technologies Corporation
$15.50
0.00%
HEALTHCARE · Cap: $1.82B
MRK
Merck & Company Inc
$120.60
+0.84%
HEALTHCARE · Cap: $283.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 19799% more annual revenue ($65.77B vs $330.51M). MRK leads profitability with a 13.6% profit margin vs -0.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).
DVAX
Hold45
out of 100
Grade: D+
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DVAX.
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$120.60
$39.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.2% revenue growth
0.7% earnings growth
Smaller company, higher risk/reward
Operating margin of 0.2%
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DVAX
DVAX has a balanced fundamental profile.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : DVAX
The primary concerns for DVAX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
DVAX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
DVAX carries more volatility with a beta of 0.93 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 45/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dynavax Technologies Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?